Quench Medical

Quench Medical is tackling the significant unmet need in treating lung diseases, particularly lung cancer, by developing a targeted inhalation drug delivery platform. Its core technology is designed to overcome the lung's natural defenses and the limitations of current systemic and inhaled therapies, enabling high local drug concentrations in the lungs with lower systemic exposure. Led by a founder with a physics and medical device background and supported by an experienced executive team, the company has raised seed funding to advance its pipeline. Quench aims to improve patient outcomes by enhancing the therapeutic index of existing and novel drugs through direct pulmonary administration.

Proprietary aerosol formulation and dry powder inhalation device technology designed to deliver high concentrations of drug deep into lung tissue while minimizing systemic exposure.

Competition includes older, less efficient standard-of-care inhalation devices (nebulizers, DPIs, pMDIs) and the entrenched use of systemic IV therapies. Quench also likely competes with other biotechs developing targeted pulmonary delivery systems for oncology, though the field remains nascent with high barriers to entry due to technical complexity.